StemCell Institute

StemCell Institute ROA

The Return on Assets (ROA) of StemCell Institute (7096.T) as of Oct 31, 2026 is 1.92 %. In the previous year, Return on Assets (ROA) was 5.13 % — a change of -62.61% (lower).

ROA

1.92 %

YoY

-62.61%

Last updated:

In 2026, StemCell Institute's return on assets (ROA) was 1.92 %, a -62.61% increase from the 5.13 % ROA in the previous year.

The StemCell Institute ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2019
5.08 JPY
Jan 1, 2020
7.77 JPY
Jan 1, 2021
1.58 JPY
Jan 1, 2022
2.56 JPY
Jan 1, 2023
3.40 JPY
Jan 1, 2024
4.72 JPY
Jan 1, 2025
5.13 JPY
Jan 1, 2026
1.92 JPY
The StemCell Institute ROA history
YEARROAYoY
1.92 %-62.61%
5.13 %+8.80%
4.72 %+38.77%
3.40 %+32.96%
2.56 %+62.27%
1.58 %-79.72%
7.77 %+53.06%
5.08 %+71.45%
2.96 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

StemCell Institute Stock analysis

What does StemCell Institute do? StemCell Institute KK operates a cell bank business segment focused on storing umbilical cord blood and cord tissue. The company collects umbilical cord blood from pregnant women through contracts with domestic cooperative hospitals, including university hospitals and obstetric clinics, then processes and stores the stem cells at its centers in Minato-ku, Tokyo, and Midori-ku, Yokohama. The firm generates revenue by charging customers for the separation, storage, and long-term preservation of stem cells, targeting expectant parents seeking future medical options. Its primary customer segment consists of pregnant women who sign storage contracts before childbirth. The company develops regenerative medicine products and new treatment methods, expanding its offerings beyond basic storage. It also invests in childbirth and childcare-related business areas, aligning with its core cell bank operations. StemCell Institute KK's revenue streams include fees for umbilical cord blood banking services and potential future sales of regenerative medicine products developed through its research and development efforts. StemCell Institute KK's business model centers on long-term storage contracts with customers, leveraging its cell processing and storage infrastructure. The firm's revenue is derived from upfront and recurring fees associated with the collection, processing, and preservation of stem cells from umbilical cord blood, with no mention of additional revenue sources such as partnerships or external investments in the provided description. StemCell Institute is one of the most popular companies on Eulerpool.

ROA Details

Understanding StemCell Institute's Return on Assets (ROA)

StemCell Institute's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing StemCell Institute's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider StemCell Institute's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in StemCell Institute’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about StemCell Institute stock

Return on Assets (ROA) of StemCell Institute is 1.92 % in 2026.

Return on Assets (ROA) of StemCell Institute changed from 5.13 % to 1.92 %, representing a -62.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) StemCell Institute since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s StemCell Institute with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — StemCell Institute

All Key Metrics — StemCell Institute